Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product ...
Q2 2026
Aug 11, 2026
Q1 2026
May 11, 2026
FY 2025
Mar 20, 2026
Q4 2025
Q3 2025
Nov 7, 2025